155 related articles for article (PubMed ID: 35262846)
1. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Chen W; Bello A; Murthy B
Clin Pharmacokinet; 2022 Jun; 61(6):857-867. PubMed ID: 35262846
[TBL] [Abstract][Full Text] [Related]
2. Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.
Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Bello A; Murthy B
Clin Pharmacokinet; 2022 Oct; 61(10):1405-1416. PubMed ID: 35906349
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
Perera V; Wang Z; Lubin S; Ueno T; Shiozaki T; Chen W; Xu X; Seiffert D; DeSouza M; Murthy B
Sci Rep; 2022 Mar; 12(1):5165. PubMed ID: 35338177
[TBL] [Abstract][Full Text] [Related]
4. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
[TBL] [Abstract][Full Text] [Related]
5. Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor.
Perera V; Wang Z; Lubin S; Christopher LJ; Chen W; Xu S; Seiffert D; DeSouza M; Murthy B
Cardiol Ther; 2022 Sep; 11(3):407-419. PubMed ID: 35641780
[TBL] [Abstract][Full Text] [Related]
6. Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor.
Perera V; Wang Z; Lubin S; Christopher LJ; Chen W; Xu S; Seiffert D; DeSouza M; Murthy B
Sci Rep; 2022 Dec; 12(1):22239. PubMed ID: 36564395
[TBL] [Abstract][Full Text] [Related]
7. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
9. Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
Fan B; Dai D; Cohen M; Xu H; Yin F; Nagaraja R; Mobilia M; Almon C; Basile FG; Yang H
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):99-109. PubMed ID: 32648303
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Piscitelli J; Chen J; LaBadie RR; Salageanu J; Chung CH; Tan W
Clin Drug Investig; 2022 Mar; 42(3):221-235. PubMed ID: 35195881
[TBL] [Abstract][Full Text] [Related]
12. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
Wong PC; Crain EJ; Bozarth JM; Wu Y; Dilger AK; Wexler RR; Ewing WR; Gordon D; Luettgen JM
J Thromb Haemost; 2022 Feb; 20(2):399-408. PubMed ID: 34752670
[TBL] [Abstract][Full Text] [Related]
13. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment.
Taylor L; Crockett J; Tayo B; Morrison G
J Clin Pharmacol; 2019 Aug; 59(8):1110-1119. PubMed ID: 30921490
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
Mercier AK; Sunnåker M; Ueckert S; Pawlik T; Henricson E; Molodetskyi O; Law GC; Parker VER; Oscarsson J
Clin Pharmacokinet; 2023 Dec; 62(12):1713-1724. PubMed ID: 37801266
[TBL] [Abstract][Full Text] [Related]
17. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
Chen X; Cui X; Pognan N; Quinlan M; Kapoor S; Rahmanzadeh G; Giovannini M; Marbury TC
Br J Clin Pharmacol; 2022 Jan; 88(1):91-102. PubMed ID: 34046915
[TBL] [Abstract][Full Text] [Related]
19. Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment.
Frost CE; Ly V; Garonzik SM
Drugs R D; 2021 Dec; 21(4):375-384. PubMed ID: 34363188
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
